Tenofovir disoproxil fumarate is a prodrug of tenofovir, a nucleotide analogue reverse transcriptase inhibitor (nRTI) that causes premature termination of DNA transcription. In a T cell line and primary blood lymphocytes, the antiviral activity of tenofovir disoproxil was shown to be more than 100-fold greater than tenofovir because of its rapid intracellular uptake. Tenofovir disoproxil fumarate has been used alone and in various combinations for the prevention and treatment of HIV/AIDS and chronic hepatitis B infections and is on the World Health Organization′s List of Essential Medicines.
Tenofovir disoproxil fumarate is a prodrug of tenofovir, a nucleotide analogue reverse transcriptase inhibitor (nRTI); anti-retroviral.
Tenofovir disoproxil fumarate (tenofovir DF) is a nucleotide analogue with activity against retroviruses, such as human immunodeficiency virus (HIV)-1, HIV-2 and hepadnaviruses.
AIDS (London, England), 30(15), 2315-2321 (2016-06-23)
The objective was to determine whether maraviroc (MVC) has unique neurocognitive benefits in the context of initial antiretroviral therapy (ART). Randomized, double-blind, placebo-controlled, 48-week trial. Participants were enrolled in US AIDS Clinical Trials Group clinical trial sites. Total 262 ART-naive
Expert opinion on drug safety, 15(9), 1287-1294 (2016-07-09)
Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors approved as pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV). Prophylactic TDF-based regimens have been shown to reduce the risk of HIV infection by 74 to 92% among